Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol open-label extension in ALS
NCT03836716Phase 3Terminated
- Sponsor
- Zevra Therapeutics
- Start
- Sep 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of arimoclomol in amyotrophic lateral sclerosis (ALS), sponsored by Zevra Therapeutics. Primary endpoints: Treatment-emergent Adverse Events, Clinical Safety Laboratory Tests (Hematology, Clinical Chemistry, Urinalysis) at Week 76 and 2 more. Started Sep 2019; status: terminated.
02
Drugs
arimoclomol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03836716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836716.